Abstract Claims Description Full Text

Abstract

The invention provides a novel method of treating respiratory diseases, e.g., pediatric asthma, in a continuing regimen with not more than one daily dose of the drug budesonide using a nebulizer.

Other References

• International Patient Package Leaflet for Pulmicort® suspension for nebulisation 0.125 mg/ml, 0.25 mg/ml and 0.5 mg/ml, ASTRA, approved by Thor-Bjorn Conradson, Aug. 18, 1994 version, pp. 1-8.
• Dunn et al., “Inhaled Corticosteroids in Severe Bronchopulmonary Dysplasia (BDP),” No. 1263, Pediatric Research 25 (4 Part 2):213A, 1989.
• Dunn et al., “Nebulized Steroids for Bronchopulmonary Dysplasia (BDP)-A Randomised, Double-Blind Cross-Over Study,” Pediatr. Res. 31 (4 pt 2):201A, 1992.
• Georgitis, “A Study of Once-A -Day Budesonide Nebulizing Suspension (BNS) and Placebo (PBO) in Asthmatic Children Aged Six Months to Eight Years,” Chest 112(3):375, Sep. 1997 Supplement.
• Goodwin, “An uncontrolled assessment of nebulised budesonide in the treatment of acute infantile bronchiolitis,” British Journal of Clinical Research 6:113-119, 1995.
• Husby et al., “Treatment of croup with nebulised steroid (budesonide): a double blind, placebo controlled study,” Archives of Disease in Childhood 68:352-355, 1993.
• Jonasson et al., #P1441 “Clinical efficacy of a low dose inhaled budesonide in children with mild asthma previously not treated with steroids,” The European Respiratory Journal 10(25):221s-222s, 1997.
• McCarty, “of ‘Nebuhaler’ and face-mask in young asthmatic children,” The Lancet 335:983-984, 1990.
• McCarthy, “The use of a once daily inhaled glucocorticosteroid (budesonide) in the management of childhood asthma,” British Jounal of Clinical Research 4:55-61, 1993.
• Möller et al., #0778 “Administration of Budesonide via Turbuhaler® . . . in Children with Asthma,” Eur.Respir.J. 9(23):115s, 1996.
• Morice et al., “A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease,” Clinical Pharmacology & Therapeutics 60:675-678, 1996.
• Pearlman, P42 “HPA-Axis function in Asthmatic Infants & Young Children Treated with Budesonide Nebulizing Suspension (BNS) or Placebo (PBO) Once-A-Day (QD),” Annual Meeting ACAAI, San Diego, CA (USA) Nov. 7-12, 1997.
• Reijonen et al., “Anti-inflammatory Therapy Reduces Wheezing After Branchiolitis,” Arch Pediatr. Adolesc. Med. 150:512-517, 1996.
• Takao et al., “Effects of Inhaled Nebulized Steroids (Budesonide) on Acute and Chronic Lung Function in Heart-Lung Transplant Patients,” Transplantation Proceedings 27:1284-1285, 1995.
• Weiner et al., “Long term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma,” Thorax 50:1270-1273, 1995.
• de Blic et al., “Efficacy of neubulized budesonide in treatment of severe infantile asthma: A double-blind study”, J. Allergy Clin. Immunol. 98:14-20, 1996.
• Godrey et al., “Nebulised Budesonide in Severe Infantile Asthma”, The Lancet, II:851-852, 1987.
• Grimfeld, “Long-term Study of Nebulised Budesonide in Young Children With Moderate to Severe Asthma”, Eur. Resp. J., 7:27s, 1994.
• Ijangovan et al., “Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension”, Archives of Disease in Childhood, 68:356-359, 1993.
• Vikre-Jorgensen et al., “Dose Titration of Nebulized Budesonide in Young Children”, Pediatric Pulmonology, 23:270-277, 1997.
• Pedersen et al., “Budesonide suspension for nebulisation in children with asthma”, Eur. Respir. J., 2(Suppl. 8):647S, 1989.
• Volovitz et al., “Rapid induction of clinical response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes”, J. Allergy Clin. Immunol. 101:464-469, 1998.
• Wennergren et al., “Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers”, Acta Paediatr, 85:183-189, 1996.